Interviewed by Steven E. Greer, MD
Barbara Giesser, MD, neurologist and Medical Director of the Multiple Sclerosis Center at UCLA, discusses the soon-to-be-approved new therapy for MS called BG-12 (fumarate), made by Biogen Idec. Biogen also makes Tysabri, which is known to cause the very serious adverse event of PML caused by the JC virus.
Dr. Giesser discusses whether BG-12 will be rapidly adopted as a new first-line therapy, and also replace existing options for failed first line therapy, such as Gilenya and Tysabri. She then reviews the recent NEJM publications on BG-12.